Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TGF-beta induced TARBP2 interacting long non-coding RNA (TGILR)
- Target
- TGILR
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
TGF-beta induced TARBP2 interacting long non-coding RNA (TGILR) is a long non-coding RNA (lncRNA) located at chromosome 6p25.2 that is transcriptionally activated by the canonical TGF-beta/SMAD3 signaling pathway, particularly in cancer. TGILR directly interacts with the RNA-binding protein TARBP2, destabilizing it and consequently perturbing microRNA biogenesis—specifically reducing levels of tumor-suppressive miR-1306 and miR-33a. This promotes the activation of EMT-related transcriptional programs (notably via TCF4), thereby enhancing gastric cancer cell proliferation, invasion, and metastasis. High TGILR expression is closely associated with poor prognosis and lymph node metastasis in gastric cancer, and constitutes a potential prognostic biomarker and putative therapeutic target in the tumor microenvironment, specifically where TGF-beta signaling is overactivated due to cancer-associated fibroblast infiltration[1][5].
- Other names
- AL590004.3RP1-140K8.5ENSG00000260604TGFbeta-induced lncRNA
02
Mechanism of action
Not applicable; as an lncRNA, TGILR is not (as yet) the direct molecular target of existing approved drugs. Research focuses on its knockdown or the inhibition of its upstream pathway (e.g., TGF-beta or CAF-targeted therapies)[1].
03
Biological functions
Regulation of microRNA biogenesisPromotion of epithelial-mesenchymal transition (EMT)Regulation of cell proliferationRegulation of cell invasionOther (e.g., transcriptional regulation via protein interaction)
04
Disease associations
CancerSpecifically, gastric cancer (GC)Cancer metastasis
05
Safety considerations
Not established; clinical targeting not reported. Potential concerns for lncRNA-targeting therapy include off-target effects and delivery challenges, but this is speculative.
06
Biomarkers
TGILR overexpression as a prognostic biomarker for lymph node metastasis and poor survival in gastric cancer[1].TGILR expression is an independent prognostic factor in GC[1].
Beyond the preview
Go deeper on TGF-beta induced TARBP2 interacting long non-coding RNA (TGILR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGF-beta induced TARBP2 interacting long non-coding RNA (TGILR).